港股異動 | 康希諾生物-B(6185.HK)漲逾6% 披露“克威莎”吸入劑型新冠疫苗最新臨牀研究進展
格隆匯10月18日丨康希諾生物-B(6185.HK)高開高走,現漲逾6%,報227.2港元,總市值562億港元。10月15日,康希諾生物股份公司首席科學官朱濤博士分享了“克威莎”吸入劑型的最新臨牀研究進展。研究發現,接種2劑滅活疫苗後6個月,序貫加強1劑“克威莎”吸入劑型,中和抗體水平相比加強之前升高250-300倍;若同源加強1劑滅活疫苗,中和抗體水平相比加強前升高30倍。可見,以吸入型腺病毒載體新冠疫苗進行異源序貫加強,相較第三針滅活疫苗加強更有優勢。以吸入式序貫接種可誘導極高水平的IgG抗體和細胞免疫反應,以吸入式加強的抗體升高倍數,約是以一劑滅活疫苗加強的7-8倍。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.